Aveo overview & day to day resources
Transcript of Aveo overview & day to day resources
![Page 1: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/1.jpg)
Welcome to Your AVEO Orientation
2012
CONFIDENTIAL
1
![Page 2: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/2.jpg)
Orientation Schedule – Day 1
Time Topic Facilitator
9:00 AM Breakfast and AVEO Overview Senior Management
9:45 AM AVEO Day-to-Day Resources Tracey Janesheski, HR Associate
10:00 AM Keeping the Workplace Safe Safety
10:15 AM Your AVEO Benefits & EE Photo Jaimie Mailander, HR Associate
12:00 PM Lunch Hiring Manager
2nd Day
9:30 AMQuality Assurance Orientation
Within 1st 60 DaysCheck-In with Your HR Business Partner
Within 1st 60 Days Legal Orientation Joe Vittiglio, Senior VP & General Counsel
27/17/2013 2 CONFIDENTIAL
![Page 3: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/3.jpg)
Who We Are
37/17/2013 3 CONFIDENTIAL
![Page 4: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/4.jpg)
4
The AVEO Executive Committee
From top left corner: Tuan Ha-Ngoc, Jeno Gyuris, Murray Robinson, David Johnston.
Seated, from left: Elan Ezickson, Michael Bailey, Nell Jones, Joseph Vittiglio, Bill Slichenmyer
7/17/2013 4 CONFIDENTIAL
![Page 5: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/5.jpg)
Tuan Ha-NgocPresident/CEO
Joseph VittiglioSr. VP & General
Counsel
-Intellectual Property
Nell JonesSr. VP, Human
Resources
Elan EzicksonExecutive VP &
COO
-Medical Affairs-Technical Operations-Program & Alliance
Management
Michael BaileyChief Commercial
Officer
Commercial & Marketing
Jeno GyurisCSO
-Translational Research-Preclinical
Development-Bioinformatics
David JohnstonCFO
-Finance-Investor Relations
-Facilities-IT
Bill SlichenmyerCMO
-Clinical-Pharmacovigilance
-Biometrics-Regulatory Affairs
Carole Varanelli VP Quality
Rob KloppenbergVP, Corp. Comm. & Public Affairs
The AVEO Organization
![Page 6: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/6.jpg)
CLINICAL ACTIVITIES AND PIPELINE DEALS
HRP AND HRP DEALS
MERGER OF HRP & PRODUCTS/CLINICAL PROGRAMS
SERIES A SERIES B SERIES C SERIES D SUCCESSFUL IPO PIPE FOLLOW-ON
TIVOZANIB PH 2 RCC STUDY INITIATED
FICLATUZUMAB PH 1 INITIATED
AVEO REGAINSRIGHTS TO
FICLATUZUMAB
TIVO-1INITIATED FICLATUZUMAB
PH 2 NSCLC INITIATED
BATON-RCC
BATON-CRC
2002-2012: A Decade of Delivery
2002 | | | | | 2012 6
![Page 7: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/7.jpg)
Human Response Platform™: Insights into Cancer Biology
7/17/2013 CONFIDENTIAL7
U.S. Patent No. 6,639,121 Issued in 2003
Discovery and
validation of
functionally relevant
targets
Maturing pipeline of
novel functional
antibodies
Biomarker-driven identification of responsive patient populations
Genetic signatures of tumors informs rational choice of drug combinations
Biomarker data provides
opportunity to optimize
benefits in selected patients
Supports pricing and
reimbursement
![Page 8: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/8.jpg)
Building A Sustainable Pipeline
7/17/2013 CONFIDENTIAL8
= FOUNDATION FOR BIOMARKER CLINICAL STATEGIES
*Aveo and Astellas Pharma Inc. have a worldwide agreement to co-develop and commercialize tivozanib outside of Asia
**Anti-ErbB3 program is strategically partnered with Biogen Idec
![Page 9: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/9.jpg)
7/17/2013 CONFIDENTIAL9
TIVOZANIB
Potent, Selective and
Long Half-Life Inhibitor
of All Three VEGF
Receptors
![Page 10: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/10.jpg)
RCC market valued at $2B WW1
Despite advances, unmet medical need persists2
Tivozanib: Potential Standard of Care in First-Line RCC
• Current therapies provide less than
12 months of first-line PFS and
therefore there remains a significant
unmet need2
• Reducing the dosage or delaying
treatment of therapies due to AEs
(fatigue, diarrhea and hand-foot
syndrome) is a major limitation2
• Many patients cannot tolerate
current therapies for a long period of
time, impacting potential to achieve
maximal efficacy2
7/17/2013 CONFIDENTIAL101. Wolters Kluwer and IMS Health
2. Campbell Alliance interviews with 7 KOLs. Aug, 8 through Aug. 12, 2011.
Improved EfficacyImproved Safety
and Tolerability
![Page 11: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/11.jpg)
7/17/2013 CONFIDENTIAL
TIVO-1 Top-Line: Statistically Significant Superiority
• Well-tolerated safety profile consistent with Phase 2– Hypertension was most common side effect; on-target class effect and
manageable
– Phase 2 experience:
• Low rate of dose reductions and interruptions, and serious side effects (grade 3/4)
• Hypertension and dysphonia most commonly reported side effects; both mechanism-related, manageable and reversible
• Side effects commonly associated with other VEGFR inhibitors (diarrhea, fatigue and hand-foot syndrome) were notably low
11
SAFETY
EFFICACY
Median PFS / Treatment Naïve (70% of overall)
Tivozanib 12.7 months
Sorafenib 9.1 months
Median PFS / Overall Study
Tivozanib 11.9 months
Sorafenib 9.1 months
![Page 12: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/12.jpg)
Our Total Approach to Patient
7/17/2013 CONFIDENTIAL12
AccessDisease Management
AdvocacySupport
Predictive
Biomarkers
Efficacy Tolerability
![Page 13: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/13.jpg)
Partnership with Astellas
• In February 2011, AVEO and Astellas entered into a worldwide
agreement outside of Asia to develop and commercialize tivozanib
for the treatment of a broad range of cancers.
Astellas, located in Tokyo, Japan, is a pharmaceutical company
with approximately 16,800 employees worldwide
• AVEO will be responsible for the manufacturing of tivozanib and
lead commercialization in North America
• Astellas will lead commercialization in the European Union
• AVEO and Astellas plan to jointly conduct and fund the expansion
of tivozanib clinical development into additional solid tumor types.
CONFIDENTIAL137/17/2013
![Page 14: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/14.jpg)
Where We are Today
• 220+ employees
• US and EU field presence (Germany, UK, France)
14
Cambridge, MA
7/17/2013 14 CONFIDENTIAL
Windsor, UK
![Page 15: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/15.jpg)
AVEO Clinical Trial Sites and MSL Locations
CONFIDENTIAL157/17/2013
RCC KOL Location
CCC Location
Current MSL
Location
![Page 16: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/16.jpg)
16
Future AVEO Headquarters:650 East Kendall
7/17/2013 16
![Page 17: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/17.jpg)
Your AVEO Day-to-Day Resources
7/17/2013 CONFIDENTIAL17
![Page 18: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/18.jpg)
New Hire Resources on the AVEO Insider
18http://aveo/metadot/index.pl?id=3139&isa=Category&op=show7/17/2013 18 CONFIDENTIAL
![Page 19: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/19.jpg)
7/17/2013 CONFIDENTIAL19
AVEO Policies
• AVEO employees are required to read and acknowledge receipt
of the following Company policies– Non-Discrimination & Non-Harassment
– Time Away From Work
– Electronic Communications & Info Systems
– Family & Medical Leave Act
– Laboratory Notebook Policy
– Insider Trading
– Disclosure Policy
– Written Comprehensive Information Security Program (WISP)
• May be required if as part of your position you have access to certain sensitive information
– Overtime and Holiday Policy
• Required only if you are an hourly, or non-exempt, employee
JULY 17, 2013 CONFIDENTIAL19
![Page 20: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/20.jpg)
Staying Informed, Getting Involved
• Quarterly All-Company Meetings
• Annual Summer Outing
• Annual Post-Holiday Celebration
• Various charitable events
20©2012 Vertex Pharmaceuticals Incorporated7/17/2013 20 CONFIDENTIAL
![Page 21: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/21.jpg)
2012 Summer Events : 10th Anniversary Year
7/17/2013 CONFIDENTIAL21
• Celebration at Fenway Park
• Guided tour, dinner, AVEO apparel
• Prouty Ride to benefit the Norris Cotton
Cancer Center
• Second Quarter all company meeting &
poster session
• Day of Community Service
• Corporate Donation of $10,000 in the
name of all employees to the Jimmy
FundJULY 17, 2013 CONFIDENTIAL21
![Page 22: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/22.jpg)
The AVEO Way: Putting the Patient First
7/17/2013 22 CONFIDENTIAL
AVEO Oncology is…
…passionate in our pursuit of improving the lives of cancer patients…
…powered by innovation…
…supportive of a creative and collaborative culture…
…committed to creating value for our shareholders.
This is the AVEO Way – the Human Response.
![Page 23: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/23.jpg)
AVEO Rewards and Recognition Program
• Annual CEO Award - $5,000
• Executive Team Award - $500
• Team Award - $150 AmEx Gift Card
• Spot Award (Individual) - $150 AmEx Gift Card
• Thanks Award - $25 AmEx Gift Card
AVEO’s CEO AwardRecipients:2012 – Andrew Strahs, Sr. Director, Biometrics
7/17/2013 23 CONFIDENTIAL
![Page 24: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/24.jpg)
Connect with Your AVEO Ambassador
• Ambassadors are employees at all levels who:– Know the culture – Know how to get things done – Convey practical knowledge
• Your Ambassador will help you navigate our campus and culture for the first 30 days
247/17/2013 24 CONFIDENTIAL
![Page 25: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/25.jpg)
AVEO Employee Referral Program
257/17/2013 25 CONFIDENTIAL
![Page 26: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/26.jpg)
26
Current AVEO Campus Map
7/17/2013 26 CONFIDENTIAL
![Page 27: Aveo overview & day to day resources](https://reader035.fdocuments.net/reader035/viewer/2022062419/55a1fd591a28ab144c8b46a3/html5/thumbnails/27.jpg)
27
Future AVEO Headquarters:650 East Kendall
7/17/2013 27